JP2015524808A - アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法 - Google Patents

アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法 Download PDF

Info

Publication number
JP2015524808A
JP2015524808A JP2015524450A JP2015524450A JP2015524808A JP 2015524808 A JP2015524808 A JP 2015524808A JP 2015524450 A JP2015524450 A JP 2015524450A JP 2015524450 A JP2015524450 A JP 2015524450A JP 2015524808 A JP2015524808 A JP 2015524808A
Authority
JP
Japan
Prior art keywords
apolipoprotein
apoa
biologically active
active analog
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524808A5 (enExample
Inventor
ソウ，パトリック
リー，シヤオミーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of JP2015524808A publication Critical patent/JP2015524808A/ja
Publication of JP2015524808A5 publication Critical patent/JP2015524808A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015524450A 2012-07-25 2013-07-25 アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法 Pending JP2015524808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675659P 2012-07-25 2012-07-25
US61/675,659 2012-07-25
PCT/US2013/052078 WO2014018763A2 (en) 2012-07-25 2013-07-25 Method of treating type i diabetes using apolipoprotein aiv

Publications (2)

Publication Number Publication Date
JP2015524808A true JP2015524808A (ja) 2015-08-27
JP2015524808A5 JP2015524808A5 (enExample) 2016-08-25

Family

ID=48916270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524450A Pending JP2015524808A (ja) 2012-07-25 2013-07-25 アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法

Country Status (6)

Country Link
US (1) US9730980B2 (enExample)
EP (1) EP2877197A2 (enExample)
JP (1) JP2015524808A (enExample)
AU (1) AU2013295721B2 (enExample)
CA (1) CA2878695A1 (enExample)
WO (1) WO2014018763A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620404T3 (es) 2011-01-19 2017-06-28 University Of Cincinnati Apoliproteína AIV como péptido antidiabético
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015198A1 (fr) * 1992-01-27 1993-08-05 Rhone-Poulenc Rorer S.A. Polypeptides derives de l'apolipoproteine aiv humaine, leur preparation et leur utilisation
JP2005502332A (ja) * 2001-07-26 2005-01-27 ジェンセット ソシエテ アノニム Ｇｍｇ−２ポリヌクレオチド及びポリペプチド並びにそれらの使用
JP2005511088A (ja) * 2001-10-05 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム Ｇｚｉｐポリヌクレオチドおよびポリペプチドならびにその使用
JP2007527873A (ja) * 2004-03-01 2007-10-04 ペプチミューン，インコーポレイテッド 自己免疫疾患の治療のための方法および組成物
WO2007123225A1 (ja) * 2006-04-24 2007-11-01 Astellas Pharma Inc オキサジアゾリジンジオン化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
PL374126A1 (en) 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
AU2009226246A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103788043B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
CA2780460C (en) * 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
ES2620404T3 (es) 2011-01-19 2017-06-28 University Of Cincinnati Apoliproteína AIV como péptido antidiabético
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015198A1 (fr) * 1992-01-27 1993-08-05 Rhone-Poulenc Rorer S.A. Polypeptides derives de l'apolipoproteine aiv humaine, leur preparation et leur utilisation
JP2005502332A (ja) * 2001-07-26 2005-01-27 ジェンセット ソシエテ アノニム Ｇｍｇ−２ポリヌクレオチド及びポリペプチド並びにそれらの使用
JP2005511088A (ja) * 2001-10-05 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム Ｇｚｉｐポリヌクレオチドおよびポリペプチドならびにその使用
JP2007527873A (ja) * 2004-03-01 2007-10-04 ペプチミューン，インコーポレイテッド 自己免疫疾患の治療のための方法および組成物
WO2007123225A1 (ja) * 2006-04-24 2007-11-01 Astellas Pharma Inc オキサジアゾリジンジオン化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, vol. 109, no. 24, JPN6017018248, 12 June 2012 (2012-06-12), pages 9641 - 9646, ISSN: 0003562540 *

Also Published As

Publication number Publication date
EP2877197A2 (en) 2015-06-03
WO2014018763A3 (en) 2014-03-20
AU2013295721A1 (en) 2015-02-05
WO2014018763A2 (en) 2014-01-30
US20150164986A1 (en) 2015-06-18
AU2013295721B2 (en) 2017-07-20
US9730980B2 (en) 2017-08-15
CA2878695A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
JP6794409B2 (ja) シータデフェンシンによる炎症性プロテアーゼの遮断
US20240207207A1 (en) Methods for mitigating and preventing proteostasis-based injuries
US20250154199A1 (en) Peptides for treating pain or reducing pain sensitivity
CN110087666B (zh) 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
CN102584976B (zh) 一种人血清淀粉样蛋白a1及其制备方法和应用
US10351598B2 (en) Peptide with anti-obesity and anti-diabetic efficacy and use thereof
US20200138903A1 (en) Socs1-derived peptide for use in chronic complications of diabetes
US9730980B2 (en) Method of treating type I diabetes using apolipoprotein A-IV
US12178848B2 (en) Methods and compositions for the treatment of exocrine pancreatic insufficiency
WO2023094581A1 (en) Compositions for the treatment of glioblastoma
EP2708233A1 (en) Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
JP6033433B2 (ja) アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
KR20230159847A (ko) 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법
US20070218504A1 (en) Human leptin-derived polypeptides and uses thereof
US20220033470A1 (en) Compositions Comprising Sortilin-1
WO2020094002A1 (zh) 抗癫痫的毒素Martentoxin及其应用
WO2017206898A1 (en) Compositions and methods for treating metabolic diseases
CN104511028B (zh) Klf9基因在抑制肝癌中的应用
WO2020237803A1 (zh) Mrg15蛋白或基因作为靶点在代谢疾病治疗和预防中的应用
JP2012067081A (ja) 疼痛の治療剤
WO2025178019A1 (ja) 繊毛病治療用医薬組成物
US20170326208A1 (en) Treatment of diseases asssociated with fat accumulation
JP2011219375A (ja) オルニチンアミノトランスフェラーゼ酵素活性阻害剤の使用
JP2025537759A (ja) 肥満を治療するための組成物および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171214